Frauenheilkunde up2date, Inhaltsverzeichnis Frauenheilkunde up2date 2015; 9(05): 365-378DOI: 10.1055/s-0033-1358186 Allgemeine Gynäkologie und gynäkologische Onkologie Georg Thieme Verlag KG Stuttgart · New York Interdiziplinäre Notfallsituationen in der Behandlung gynäkologischer Malignome Maximilian Mögele , Stefan Buchholz , Olaf Ortmann Artikel empfehlen Abstract Artikel einzeln kaufen Alle Artikel dieser Rubrik Volltext Referenzen Literatur 1 Ralston SH. Pathogenesis and management of cancer associated hypercalcaemia. Cancer Surv 1994; 21: 179-196 2 Mundy GR, Bertolini DR. Bone destruction and hypercalcemia in plasma cell myeloma. Semin Oncol 1986; 13: 291-299 3 Alipov GK, Ito M, Nakashima M et al. Expression of parathyroid hormone-related peptide (PTHrP) in gastric tumours. J Pathol 1997; 182: 174-179 4 Payne RB, Little AJ, Williams RB et al. Interpretation of serum calcium levels in patients with abnormal serum proteins. Br Med J 1973; 4: 643-646 5 Berenson JR. Treatment of hypercalcemia of malignancy with bisphosphonates. Semin Oncol 2002; 29: 12-18 6 Klebl F, Krause SW. Akuttherapie onkologischer Notfälle. Intensivmed 2007; 44: 74-87 7 Hutcherson DA, Gammon DC, Bhatt MS et al. Reduced-dose rasburicase in the treatment of adults with hyperuricemia associated with malignancy. Pharmacotherapy 2006; 26: 242-247 8 Parish JM, Marschke jr. RF, Dines DE et al. Etiologic considerations in superior vena cava syndrome. Mayo Clin Proc 1981; 56: 407-413 9 Rowell NP, Gleeson FV. Steroids, radiotherapy, chemotherapy and stents for superior vena caval obstruction in carcinoma of the bronchus: a systematic review. Clin Oncol (R Coll Radiol) 2002; 14: 338-351 10 Urruticoehea A, Mesia R, Dominguez J et al. Treatment of malignant superior vena cava syndrome by endovascular stent insertion. Experience on 52 patients with lung cancer. Lung Cancer 2004; 43: 209-214 11 Heffner JE. Diagnosis and management of malignant pleural effusions. Respirology 2008; 13: 5-20 12 Hentrich M, Hartenstein R. Behandlung maligner Körperhöhlenergüsse. Onkologe 1997; 3: 163-173 13 Feller-Kopman D, Berkowitz D, Boiselle P et al. Large-volume thoracentesis and the risk of reexpansion pulmonary edema. Ann Thorac Surg 2007; 84: 1656-1661 14 Antunes G, Neville E et al. Management of malignant pleural effusions. Thorax 2000; 55: 981-983 15 Ried M, Hofmann HS. The treatment of pleural carcinosis with malignant pleural effusion. Dtsch Arztebl Int 2013; 110: 313-318 16 Rodriguez-Panadero F, Antony VB. Pleurodesis: state of the art. Eur Respir J 1997; 10: 1648-1654 17 Hudson MM, Ness KK, Gurney JG et al. Clinical ascertainment of health outcomes among adults treated for childhood cancer. JAMA 2013; 309: 2371-2381 18 Romond EH, Jeong JH, Rastogi P et al. Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2012; 30: 3792-3799 19 Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-792 20 Schlitt A, Jordan K, Vordermark D et al. Cardiotoxicity and oncological treatments. Dtsch Arztebl Int 2014; 111: 161-168 21 Cook DJ, Guyatt GH, Salena BJ et al. Endoscopic therapy for acute non-variceal upper gastrointestinal hemorrhage: A meta-analysis. Gastroenterology 1992; 102: 139-148 22 Greten H, Jäckle S, Thonke F et al. Endoscopic therapy in non-variceal gastrointestinal bleeding. Dtsch Arztebl 2001; 98: A-604/B-492/C-464 23 Sallah S, Wan JY, Nguyen NP. Venous thrombosis in patients with solid tumors: Determination of frequency and characteristics. Thromb Haemost 2002; 87: 575-579 24 Sørensen HT, Mellemkjaer L, Olsen JH et al. Prognosis of cancers associated with venous thromboembolism. N Engl J Med 2000; 343: 1846-1850 25 Khorana AA, Kuderer NM, Culakova E et al. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 2008; 111: 4902-4907 26 Riess H, Pelzer U, Deutschinoff G et al. A prospective, randomized trial of hemotherapy with or without the low molecular weight heparin (LMWH) enoxaparin in patients with advanced pancreatic cancer: Results of the CONKO 004 trial. J Clin Oncol 2009; ASCO Abstract LBA4506. J Clin Oncol 2009; ASCO Abstract LBA4506 27 Encke A, Haas S, Sauerland S et al. S3-Leitlinie. Prophylaxe der venösen Thromboembolie (VTE). Vasa 2009; 38: 1-131 28 Guyatt GH, Akl EA, Crowther M et al. Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141: 7S-47S 29 Cohen AT, Spiro TE, Spyropoulos AC. MAGELLAN Steering Committee. Rivaroxaban for thromboprophylaxis in acutely ill medical patients. N Engl J Med 2013; 368: 1945-1946 30 Clagett GP, Andersen jr. FA, Heit JA et al. Prevention of venous thromboembolism. Chest 1995; 108: 312-334 31 Bergqvist D, Agnelli G, Cohen AT et al. ENOXACAN II investigators. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery of cancer. N Engl J Med 2002; 346: 975-980 32 van der Hulle T, Huisman MV, Klok FA. Meta-analysis of the efficacy and safety of new oral anticoagulants in patients with cancer-associated acute venous thromboembolism: reply. J Thromb Haemost 2014; 12: 2138-2139 33 Interdisziplinäre S2-Leitlinie: Lungenembolie (LE). Vasa 2005; 34: 15-24 34 Tapson VF. Acute pulmonary embolism. N Engl J Med 2008; 358: 1037-1052 35 Wan S, Quinlan DJ, Agnelli G et al. Thrombolysis compared with heparin for the initial treatment of pulmonary embolism: a meta-analysis of the randomized controlled trials. Circulation 2004; 110: 744-749 36 Wells PS, Anderson DR, Rodger M et al. Derivation of a simple clinical model to categorize patients probability of pulmonary embolism: increasing the models utility with the SimpliRED D-dimer. Thromb Haemost 2000; 83: 416-420
